Growth-hormone secretagogue research splits into two mechanisms — GHRH-pathway and GHRP/ghrelin-pathway compounds. Here is what published research found for each, side by side.
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) engineered to bind circulating albumin after injection, extending its half-life well beyond natural GHRH so it can continuously stimulate the pituitary to release growth hormone.
CJC-1295 without DAC (also called Mod GRF 1-29) is a stabilized 29-amino-acid fragment of growth hormone-releasing hormone (GHRH). Unlike the DAC-modified version, it is not engineered to bind albumin, giving it a short half-life (roughly 30-60 minutes) and a pulsatile growth-hormone-release profile closer to the body's natural GHRH signaling.
Ipamorelin is a pentapeptide that acts as a selective agonist at the ghrelin/growth hormone secretagogue receptor, stimulating GH release from the pituitary. It was developed to trigger GH release without also raising cortisol, ACTH, or other pituitary hormones the way earlier GH-releasing peptides did.
Sermorelin is a 29-amino-acid fragment of growth hormone-releasing hormone that binds pituitary receptors and stimulates the pituitary to release its own growth hormone. It was originally FDA-approved as a diagnostic agent for growth hormone deficiency and studied clinically through the 1990s.
Tesamorelin is a synthetic analog of GHRH that stimulates the pituitary to secrete growth hormone, raising IGF-1 in turn. It is an FDA-approved prescription drug under other brand names for a specific indication —a regulatory fact noted here for research-literature context, not a claim about this research-use material.
This guide summarizes published research findings only — it is not medical advice, a dosing recommendation, or a claim about safety or effectiveness for human use. For Research Purposes Only, Not For Human Consumption.